Abstract
Relationship Of Serum Free Light Chain Reduction To Best Overall Response In Phase 2 Single-Agent and Combination Studies Of Carfilzomib In Patients With Relapsed Or Relapsed and/Or Refractory Multiple Myeloma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have